Development of Cell-Based High-Throughput Assays for the Identification of Inhibitors of Receptor Activator of Nuclear Factor-Kappa B Signaling

被引:7
作者
Ashley, Jason W. [1 ]
McCoy, Erin M. [1 ]
Clements, Daniel A. [1 ]
Shi, Zhenqi [1 ]
Chen, Taosheng [2 ]
Feng, Xu [1 ]
机构
[1] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[2] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA
关键词
TUMOR-NECROSIS-FACTOR; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL OSTEOPOROSIS; ANTIRESORPTIVE TREATMENT; TNF RECEPTOR; TRAF FAMILY; RANK; BONE; MEMBER; PATHOGENESIS;
D O I
10.1089/adt.2010.0307
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Bone loss due to metabolic or hormonal disorders and osteolytic tumor metastasis continues to be a costly health problem, but current therapeutics offer only modest efficacy. Unraveling of the critical role for the receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANK ligand (RANKL), in osteoclast biology provides an opportunity to develop more effective antiresorptive drugs. The in vivo effectiveness of RANKL inhibitors demonstrates the potency of the RANKL/RANK system as a drug target. Here, we report the development of cell-based assays for high-throughput screening to identify compounds that inhibit signaling from two RANK cytoplasmic motifs (PVQEET 559-564 and PVQEQG 604-609), which play potent roles in osteoclast formation and function. Inhibitors of these motifs' signaling have the potential to be developed into new antiresorptive drugs that can complement current therapies. The cell-based assays consist of cell lines generated from RAW264.7 macrophages stably expressing a nuclear factor-kappa B-responsive luciferase reporter and a chimeric receptor containing the human Fas external domain linked to a murine RANK transmembrane and intracellular domain in which only one of the RANK motifs is functional. With these cells, specific RANK motif activation after chimeric receptor stimulation can be measured as an increase in luciferase activity. These assays demonstrated >300% increases in luciferase activity after RANK motif activation and Z'-factor values over 0.55. Our assays will be used to screen compound libraries for molecules that exhibit inhibitory activity. Follow-up assays will refine hits to a smaller group of more specific inhibitors of RANK signaling.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 42 条
[11]   Pathogenesis of bone and cartilage destruction in rheumatoid arthritis [J].
Goldring, SR .
RHEUMATOLOGY, 2003, 42 :11-16
[12]   LONG-TERM CALCITONIN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS [J].
GRUBER, HE ;
IVEY, JL ;
BAYLINK, DJ ;
MATTHEWS, M ;
NELP, WB ;
SISOM, K ;
CHESNUT, CH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (04) :295-303
[13]   Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J].
Hsu, HL ;
Lacey, DL ;
Dunstan, CR ;
Solovyev, I ;
Colombero, A ;
Timms, E ;
Tan, HL ;
Elliott, G ;
Kelley, MJ ;
Sarosi, I ;
Wang, L ;
Xia, XZ ;
Elliott, R ;
Chiu, L ;
Black, T ;
Scully, S ;
Capparelli, C ;
Morony, S ;
Shimamoto, G ;
Bass, MB ;
Boyle, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3540-3545
[14]   Receptor activator of NF-κB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase [J].
Kim, HH ;
Lee, DE ;
Shin, JN ;
Lee, YS ;
Jeon, YM ;
Chung, CH ;
Ni, JA ;
Kwon, BS ;
Lee, ZH .
FEBS LETTERS, 1999, 443 (03) :297-302
[15]   OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J].
Kong, YY ;
Yoshida, H ;
Sarosi, I ;
Tan, HL ;
Timms, E ;
Capparelli, C ;
Morony, S ;
Oliveira-dos-Santos, AJ ;
Van, G ;
Itie, A ;
Khoo, W ;
Wakeham, A ;
Dunstan, CR ;
Lacey, DL ;
Mak, TW ;
Boyle, WJ ;
Penninger, JM .
NATURE, 1999, 397 (6717) :315-323
[16]   Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].
Lacey, DL ;
Timms, E ;
Tan, HL ;
Kelley, MJ ;
Dunstan, CR ;
Burgess, T ;
Elliott, R ;
Colombero, A ;
Elliott, G ;
Scully, S ;
Hsu, H ;
Sullivan, J ;
Hawkins, N ;
Davy, E ;
Capparelli, C ;
Eli, A ;
Qian, YX ;
Kaufman, S ;
Sarosi, I ;
Shalhoub, V ;
Senaldi, G ;
Guo, J ;
Delaney, J ;
Boyle, WJ .
CELL, 1998, 93 (02) :165-176
[17]   Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis [J].
Lewiecki, E. Michael .
JOURNAL OF WOMENS HEALTH, 2009, 18 (10) :1615-1626
[18]  
Lian JB, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P93
[19]   Functional identification of three receptor activator of NF-κB cytoplasmic motifs mediating osteoclast differentiation and function [J].
Liu, W ;
Xu, DR ;
Yang, HM ;
Xu, H ;
Shi, ZQ ;
Cao, XM ;
Takeshita, S ;
Liu, JZ ;
Teale, M ;
Feng, X .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (52) :54759-54769
[20]   The TNF and TNF receptor superfamilies: Integrating mammalian biology [J].
Locksley, RM ;
Killeen, N ;
Lenardo, MJ .
CELL, 2001, 104 (04) :487-501